Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The two phenomena of extravasation and later diffusion and convection of the colloid in the extracellular matrix both result in enhanced permeation and retention of the nanoparticles [32].](https://figures.cochat.ai/paper-figures/887ab73c266443efbb3420cd636da176/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-1.jpg)
![Figure 2 Common strategies utilizing the EPR effect [109].](https://figures.cochat.ai/paper-figures/89ba4512a64543b1a593fb62b3bf1725/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In clinical settings, one of the main challenges for the delivery of macromolecules and nanomedicine to the cancer site is due to the heterogeneity of the EPR effect in solid tumors [20].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“The rapid tumor growth and improper development of blood vessels in murine tumors result in a much leakier vasculature as compared to human tumors that can lead to misinterpretation of the EPR effect [78].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“The liposomal doxorubicin extravasated and accumulated intact in tumors with a leaky vasculature [79].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180 · cited 3×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039 · cited 1×
“These nanoparticles with a size below 50 nm are mostly used for the detection of brain tumors [140].”
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864 · cited 1×
“and spleen, but large enough to avoid kidney clearance [7,8].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Research works printed but not linked: 1
- Dellian, 2000, Vascular permeability in a human tumour xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513
Cited by
Items 601–657 of 657
Qureshi, S. A., Nadaf, A., Imtiyaz, K., Rizvi, M. M. A., Hasan, N., & Ahmad, F. J. (2026) · BioNanoScience · doi:10.1007/s12668-026-02668-5
“From this perspective, synthesis of PLGA NPs co-encapsulated with leukocyte membrane serves as the drug carrier for targeting the tumor site have drawn attention towards remarkable biomimetic nano therapy that mimics like the source cells and give outstanding performance [18, 19].”
Singh, R., Yadav, P. Y., Srivastava, D., Lal, N., Tandon, N., Chaurasia, M., & Flora, S. J. S. (2026) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2026.2696023
“…moderate negative surface charge aligning with the required characteristics for stable preparation which can be passively targeted exploiting ePR [78], and provide uniform drug release [79]. a stable formulation is key for targeting as it can be readily cleared (if aggregates are formed) from…”
History, foundations, and evolution of nanomedicine
Sharma, S., & Gupta, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36532-4.00013-4
Sun, X. (2026) · cIRcle (University of British Columbia) · doi:10.14288/1.0452810
Recent advances in phytomedicine-based nano-antioxidants for redox-modulated cancer therapy
Faridi, U. A., Almutairi, F. M., Sakran, M., Zidan, N., Alalawy, A. I., Al-Awthan, Y., Akhtar, Q., & Atteia, H. (2026) · Cancer Nanotechnology · doi:10.1186/s12645-026-00401-1
“Surface modifications such as PEGylation or biomimetic coatings further reduce opsonization and uptake by the mononuclear phagocyte system, thereby pro-longing circulation time and enhancing tissue distribution (Mousavi-Kiasary et al. 2025; Subhan et al. 2021).”
Recent advancement in the codelivery of proteins and small-molecule drugs for targeted therapy
Salehi, S., & Naghib, S. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33639-3.00012-x
Huy, T. Q., & Thuy, N. T. T. (2026) · Springer eBooks · doi:10.1007/978-981-95-9777-2_7
Hassan, A., Siddiqui, N., Khan, B., & Malik, S. (2026) · Pharmaceutical Sciences and Drug Design · doi:10.51847/gz5vowolkd
Ravichandran, V., Rangarajan, T. M., Balasubramanian, S., Kumari, N., & Murugesan, C. (2026) · ChemNanoMat · doi:10.1002/cnma.70325
Yuan, Y., Okada, S., Miura, K., Suzuki, M., & Nakamura, H. (2026) · Langmuir · doi:10.1021/acs.langmuir.6c02188
Kumar, A., Singh, V., Kumar, K., Singhal, N. K., & Kumar, S. (2026) · Nanoscale · doi:10.1039/d6nr01113f
Ke, Z., Luo, T., Cheng, X., Chai, X., Zhu, Z., Huang, Z., & Wang, Z. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s616360
Kaushik, S., Fatima, J. E., Raheem, A., Barbhuiya, M. A., Thirupathi, A. T., Singh, L. P., Khan, P. A., Aparna, T. N., Pramanik, S., & Shahid, M. A. A. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02329-9 · Cited by 1
Nanomedicine for retinoblastoma: overcoming ocular barriers and advancing precision drug delivery
Grace, S. R., Alexander, A., & Enoch, I. V. M. V. (2026) · Next research. · doi:10.1016/j.nexres.2026.102207
Mobin, S. A., & Bhadange, V. A. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.70s.9
“28 these studies imply that the enhanced permeability and retention effect in clinical settings involving cancer patients has not yet been validated.”
Polymeric Nanocarriers for Controlled Drug Release
Ahmad, Z., Hassan, M. U., Maryam, H., Rehman, N. U., Abass, K. S., Fazal, A., Ilyas, M., & Yasmin, H. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-9848-8.ch005
Chuxuan, L., Yi, Z., Namei, J., Xiumei, M., Chunlin, S., & Xie, Y. (2026) · iMed · doi:10.70322/imed.2026.10007
Sonoselective Transfection of Glioma Endothelium
Debski, A. C., Gorick, C. M., Breza, V. R., Tirrell, J., Perumal, K., Nowak, K. M., Song, J., Sheybani, N., & Price, R. J. (2026) · Advanced Science · doi:10.1002/advs.76997
“However, passive NP accumulation in GBM due to leaky vasculature and the so-called “enhanced permeability and retention” (EPR) effect is highly heterogeneous within tumors and only allows a miniscule fraction of an administered dose to reach the tumor [ 20 ].”
Herskovic, J. J., & Herskovic, A. M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1812448
“Nanoparticle delivery is in fl uenced by particle size, surface charge (zeta potential), shape, and the dimensions of the local extracellular space (17, 18, 20, 21).”
Wang, J., Zhang, Z., Li, H., Teng, Y., Chen, B., Zuo, J., Li, X., Zhan, P., Fu, S., Xu, Y., et al. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s615219
“166,167 Additionally, nanocarriers can enter tumor cells through endocytosis, partially bypassing efflux pump-mediated clearance and thereby increasing intracellular drug accumulation.”
Metallinanopartikkelit kuvantamisessa ja kohdennetussa lääkeainekuljetuksessa
Niiniskorpi, E. (2026) · Jyväskylä University Digital Archive (University of Jyväskylä)
Kamal, F. Z., Lefter, R. M., Burlui, V., Ciobîcă, A. S., -, G. D., Rammali, S., Luca, A., Miler, A. A., Alim, H., Novac, O., et al. (2026) · Cancers · doi:10.3390/cancers18162592
“Studies have emphasized that although the EPR effect is pronounced and reproducible in rapidly growing murine xenograft models, they are generally less effective in human tumors [109].”
Hani, U., Hamod, M. A., Hamood, N. A., Alhamhoom, Y., Ghazwani, M., Alqahtani, F., Helal, H. A., & Osmani, R. A. M. (2026) · Pharmaceuticals · doi:10.3390/ph19081273 · Cited by 1
“Moreover, alongside passive targeting, surface modification permits active targeting for cell receptors on the tumors, thus improving treatment specificity [2].”
Jameie, L., Abbaslou, D. M., Nategi, T., Keikhosrowkiani, N., Shahshahanipour, M., Sadeghi-Kaji, F.-S., Najafi, N., Bigham, A., & Rafienia, M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108828
A redox-responsive viologen–cavitand nanocarrier for dual-function photodynamic therapy
Maslennikov, A. A., Usanyov, A. Y., Shamsutdinov, A. A., Lyubina, A. P., Парфенов, А. А., Voloshina, A. D., Nizameev, I. R., Kadirov, M. K., Fazleeva, R. R., Yanilkin, V. V., et al. (2026) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.17.78
Talouki, P. Y., Tamimi, R., & Jafaripour, N. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s633125
Self-assembled supramolecular systems for anticancer drug delivery
Baheti, R., Patole, V., Chopada, V., Kumawat, M., & Deshkar, S. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44185-1.00020-3
Current progress and future prospects of chlorin e6 (Ce6) as a therapeutic agent
Obalola, A. A., Abrahamse, H., & Kumar, S. S. D. (2026) · RSC Advances · doi:10.1039/d6ra04753j
Shetty, P., Shukla, S., Phatale, V., Devi, A., Chaure, P., Srivastava, A., Khairnar, P., & Srivastava, S. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127383
Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation
Liu, K., Yuan, X., Zhou, Y., Yuan, R., Xie, S., Chen, Y. X., Wang, P., Gao, J.-M., & Gong, Q. (2026) · Advanced Science · doi:10.1002/advs.77305
“Unlike passive accumulation, which is often associated with size-dependent transport processes [ 125 ], active targeting strategies introduce targeting modules through co-assembly [ 126 ] that enable assemblies to recognize specific tissues, cells, or even subcellular structures, conferring a…”
Fatima, M., Parveen, W., Almaneai, N. M., El-kott, A. F., Alshehri, M. A., Eltantawy, W., Kanwal, N., & Saadia, Z. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1899601
“Passive uptake increases local drug concentration relative to free drug (Subhan et al., 2021).”
Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives
Mohanty, B., Saikia, P., Pandey, P., & Bhattacharjee, C. R. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1920337
“…therapies have shown promise in improving this targeting challenges The limitations associated with passive targeting leads to the development of active targeting strategies that combine EPR-mediated accumulation with receptor-specific cellular uptake (Subhan et al., 2021).”
Dutta, A., Satapathy, T., & Sahu, P. (2026) · Journal of Applied Pharmacology and Toxicology · doi:10.69857/joapt.v2i1.40
“Conventional nanoparticle design largely treats receptor binding as a binary event without considering the spatial, temporal, and cooperative organization of receptors within the plasma membrane [4].”
Magnetic nanorobots in oncology: From targeted drug delivery to smart theranostic systems
Xiaoyu, L. I. U., Li, C., Xu, Z., Yan, Y., Liu, W. T., Li, Y., & Gao, M. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103709
“This targeting mode is passive targeting [26,27].”
Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment
Ding, W., Zhang, X., Wu, H., Congrui, Z., Xu, K., Tai, Z., & Xia, G. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s616713
“37,38 Indeed, our in vivo results strongly supported the potential of PPcJ, demonstrating significantly extended survival (mean survival time of 41.0 ± 2.2 days vs 22.4 ± 4.2 days), effective tumor suppression (86.2% tumor inhibition rate), and excellent biocompatibility.”
InfluentialSono-dynamic synergy of DOX-MBs achieves real-time imaging-guided drug delivery for breast cancer
Huang, P., Wang, J., Lu, Z., Yan, F., Yu, W., Li, W., & Luo, Q. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2736152
Shadman, M., Hashmi, A. R., Zahra, F., Ravi, R. N., Jaganathan, R., Wong, L. S., Mehta, J., Rai, P. S., Tamilanban, T., & Sekar, M. (2026) · Phytomedicine Plus · doi:10.1016/j.phyplu.2026.101047
Shoala, S. A., Abbas, H., Elbedaiwy, H. M., Shamaa, M. M., & Elsheikh, M. A. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115243
Shaikh, S. A., Mishra, A., & Havelikar, U. A. (2026) · Biomedical Analysis · doi:10.1016/j.bioana.2026.09.001
Lipid Nanoparticles at the Crossroads of Chemistry and Medicine: A Tutorial
Rogado, M. T., Wang, A., Zeng, S., Wang, Z., & Burda, C. (2026) · ACS Nanoscience Au · doi:10.1021/acsnanoscienceau.6c00096
Stealth Strategies for Cancer Nanomedicine: A Review of Immune Evasion and Tumor Targeting
Chitra, A., & Chetty, S. S. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6040052
Oyoun, F., Séguin, J., Toncheva, A., Gahoual, R., Benghouzi, P., Lannou, M., Griffete, N., Sabbah, M., Richard, C., Mignet, N., et al. (2026) · RSC Pharmaceutics · doi:10.1039/d6pm00213g
Emerging Frontiers and Future Directions in Nanomedicine: A Comprehensive Review
BHAT, R., M, H. M., Varshini, N., & SHABARAYA, A. (2024) · International Journal of Current Research in Physiology and Pharmacology (IJCRPP)
Magnetic nanoparticles in biomedicine
Bryan, J. T., Choi, C., & Wang, S. X. (2026) · Handbook of magnetic materials · doi:10.1016/bs.hmm.2026.08.001
Colloidal nanomedicine approaches for regulating cell death mechanisms in tumours
Ahsan, M. N., Chettupalli, A. K., Pathak, P., Amaravadi, D., & Jadi, R. K. (2026) · Therapeutic Delivery · doi:10.1080/20415990.2026.2731774
Adeli, F., Pourmadadi, M., Shabestari, S. M., Abdouss, H., & Abdouss, M. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100856
Shinde, R. S., & Nimbalkar, J. A. (2026) · INNOSC Theranostics and Pharmacological Sciences · doi:10.36922/itps026140013
Size-tailored natural polysaccharides for advanced drug delivery: From nano to macro
Li, Y.-X., Jing-han, Z., Jiang, M.-T., Yue-fan, L., Sun, Y.-J., Liu, Y.-X., Bao, C., & Duan, J.-L. (2026) · Food & Medicine Homology Resources · doi:10.26599/fmhr.2026.9740004
Chmiela, M., Jaroniek, P., Manzaneque, J. C. R., Balcerczak, E., Brzeziński, M., Jeleń, A. M., Mani, S., Wosiak, A., & Gonciarz, W. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10388-1
“However, the magnitude and consistency of the EPR effect vary substantially among tumors and patients, and this variability must be considered when designing nanofor-mulations [20].”
Biswal, P. P., Chandran, R., & Nair, R. V. (2026) · ChemistrySelect · doi:10.1002/slct.74879
Nanocarrier based drug delivery for rheumatoid arthritis: Current strategies and future directions
Li, N., Qu, Z., & Du, D. (2026) · Acta Pharmaceutica · doi:10.2478/acph-2026-0028
“Passive targeting exploits the EPR effect at sites of synovial hypervascularity and impaired lymphatic drainage (109).”
Alqahtani, F., Alrubiaan, S. D., Haider, N., Hani, U., Alhamhoom, Y., Ghazwani, M., Alfuhayr, T., & Osmani, R. A. M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.109062
Lu, H., Deng, C., Zhao, J., Zhang, J., Cao, A., An, F., Chen, N., & Chai, Y. (2026) · RSC Advances · doi:10.1039/d6ra06275j
Shortwave infrared silver chalcogenide quantum dots for bioimaging and theranostics
Tian, Y., Xin, F., & Zhang, X. (2026) · Chemical Communications · doi:10.1039/d6cc04283j
Folic acid-decorated nanosystems for cancer targeting: Approaches, benefits, and challenges
Patil, D. R., Bhinge, S. D., Kumbhar, P., Waghmare, P. V., Nangare, S., Siraskar, B. D., & Randive, D. S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.109105
Application of biopolymers in drug and gene delivery
Vengateswaran, H. T., Thalij, K. M., Habeeb, M., You, H. W., Kumbhar, S. T., & Ahmed, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33052-0.00012-6
Cesur, B., & Dora, D. D. (2026) · Drug Development Research · doi:10.1002/ddr.70402
Metadata
- Authors
- Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 11
- Issue
- 6
- Pages
- 571
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8234032
- OpenAlex
- W3174294541
- Semantic Scholar
- 0e274cc5538c8ce64b42706c752e9cd357ce4ede
- Cited by
- 623
- References
- 172
- Citations by year
- 2026: 116 · 2025: 167 · 2024: 148 · 2023: 106 · 2022: 82 · 2021: 4
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, cancer nanomedicine, nanotherapeutics, tumor selectivity, intravenous drug delivery, tumor microenvironment, lymphatic drainage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.